Client

Early-stage venture-backed biotechnology company, United States

Challenge

A US biotechnology company was preparing to advance its lead therapeutic programme and needed to identify qualified external partners to support discovery, preclinical development, bioanalysis, CMC activities, and manufacturing readiness. The organisation had a lean internal team and limited bandwidth to conduct comprehensive assessments across a highly fragmented CRO/CDMO landscape.

The client required an independent, science-driven evaluation of potential partners capable of supporting both immediate programme requirements and future development activities.

Aventiq Bio Approach

Aventiq Bio conducted a structured vendor identification and qualification exercise spanning multiple development functions. The objective was to identify organisations with the appropriate technical expertise, operational maturity, quality systems, and programme alignment.

Key Activities

• Mapped the global CRO and CDMO landscape relevant to programme requirements
• Evaluated scientific capabilities and therapeutic area experience
• Assessed quality systems, regulatory track records, and inspection history
• Reviewed infrastructure, capacity availability, and geographic considerations
• Analysed timelines, communication practices, and governance frameworks
• Performed comparative capability benchmarking
• Developed a risk-benefit assessment for shortlisted vendors
• Prepared decision-support materials for executive review

Outcome

Aventiq Bio delivered a curated shortlist of qualified partners together with a structured evaluation framework, enabling the client to make informed outsourcing decisions with confidence.

The exercise reduced partner selection risk, accelerated programme initiation timelines, and preserved internal resources for scientific and strategic priorities.

Client Perspective

Aventiq Bio provided a structured and objective evaluation of potential CRO and CDMO partners across multiple development disciplines. Their scientific due diligence, capability assessment, and vendor shortlisting process helped us make confident partner selection decisions while significantly reducing the time and effort required from our internal team

— Chief Executive Officer, Venture-Backed Biotechnology Company, USA